NanoBio receives contract from NIAID for pandemic flu and HIV vaccines
The initial contract from the NIAID, a subsidiary of the National Institutes of Health, is valued at $5.5 million. The contract includes an option for the study of a NE adjuvant in an HIV vaccine. If this option is exercised, the total contract value will be $10.5 million.
"With this contract support from NIAID, we will further our studies of the NE adjuvant and its important role in enhancing vaccines against challenging respiratory infections and sexually transmitted diseases," NanoBio Chief Executive Officer David Peralta said. "We look forward to moving our NanoVax-Panflu vaccine towards the clinic and on the path to commercialization."
The contract supports research and development of NanoBio's NanoVax-Panflu, a NE adjuvant mixed with a plant-based recombinant H5 pandemic influenza drug. The adjuvanted vaccine was designed to protect against infection through mucosal and systemic immunity. New research has shown that mucosal immunity is important when protecting against diseases that transfer through mucous, such as influenza and sexually transmitted diseases.
"Our most recent studies at NanoBio have tested NE-adjuvanted vaccines for respiratory syncytial virus and type 2 genital herpes, two viruses that enter the body via mucosal sites," Peralta said. "The results of these studies very clearly demonstrate the ability of the NE adjuvant to elicit mucosal immunity and the important role this type of immunity plays in protecting against disease."